New products: Piqray (alpelisib) 50, 150 and 200mg film-coated tablets

Alpelisib is licensed in combination with fulvestrant for treatment of postmenopausal women, and men, with locally advanced or metastatic breast cancer with a PIK3CA mutation, after disease progression following endocrine therapy as monotherapy.

Source:

electronic Medicines compendium